AstraZeneca (LON:AZN) Given “Buy” Rating at Jefferies Financial Group

Jefferies Financial Group reaffirmed their buy rating on shares of AstraZeneca (LON:AZN) in a report released on Friday,Digital Look reports. They currently have a £175 price objective on the biopharmaceutical company’s stock.

A number of other analysts also recently weighed in on AZN. Citigroup increased their price objective on AstraZeneca from £175 to £178 and gave the company a “buy” rating in a report on Tuesday, July 28th. Berenberg Bank reiterated a “buy” rating and issued a £175 price target on shares of AstraZeneca in a research report on Wednesday, October 7th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a £117 price target on shares of AstraZeneca in a research note on Tuesday, September 29th. Finally, Royal Bank Of Canada started coverage on AstraZeneca in a research report on Tuesday, September 8th. They set an “outperform” rating and a £145 price objective for the company. Six research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of £153.57.

AstraZeneca Stock Performance

Shares of AZN stock opened at £139.96 on Friday. AstraZeneca has a 12 month low of £114.04 and a 12 month high of £157.32. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 64.10. The firm has a market capitalization of £217.06 billion, a price-to-earnings ratio of 20.95, a PEG ratio of 0.86 and a beta of 0.21. The business’s 50-day moving average price is £123.07 and its 200-day moving average price is £134.30.

Insider Transactions at AstraZeneca

In other news, insider Michel Demare acquired 2,500 shares of the firm’s stock in a transaction on Monday, September 14th. The stock was purchased at an average price of £121.21 per share, for a total transaction of £303,025. Insiders own 0.15% of the company’s stock.

More AstraZeneca News

Here are the key news stories impacting AstraZeneca this week:

• Positive Sentiment: Q3 earnings beat expectations: AstraZeneca reported third-quarter revenue of approximately $16.21 billion, up 7% year over year, while earnings per share more than doubled Wall Street’s estimate. The company reaffirmed its fiscal 2026 revenue and core EPS outlook at constant exchange rates, reducing concerns about near-term execution. AstraZeneca Q3 2026 Earnings AstraZeneca Q3 Profit and Guidance
• Positive Sentiment: Pipeline potential remains significant: AstraZeneca’s CEO said upcoming drug trial readouts in 2027 could represent more than $20 billion in potential value, supporting the long-term growth narrative and helping justify the stock’s valuation. AstraZeneca 2027 Trial Readouts
• Positive Sentiment: Cost savings will fund innovation: The company launched a $1.5 billion savings program, with the goal of redirecting resources toward its drug-development pipeline. This could improve operating leverage and support future launches. AstraZeneca Savings Drive
• Positive Sentiment: Analyst confidence strengthened: Jefferies reaffirmed its “buy” rating and set a £175 price target, implying further upside based on its assessment of AstraZeneca’s earnings and pipeline prospects.
• Positive Sentiment: Promising lung-cancer data: A Tagrisso combination achieved a significant survival benefit in a lung-cancer trial, reinforcing the commercial prospects of one of AstraZeneca’s key oncology franchises. Tagrisso Lung Cancer Trial
• Negative Sentiment: Generic competition remains a headwind: AstraZeneca indicated that the loss of exclusivity for Farxiga is weighing on results, although stronger oncology sales are currently more than offsetting the impact. AstraZeneca Cancer Drugs and Farxiga

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.